Cost effectiveness of fluvoxamine in the treatment of recurrent depression in france

PharmacoEconomics

Volumn 14, Issue 4, 1998, Pages 433-445

  Nuijten, Mark ^a   Hadjadjeba, Lionel ^b   Evans, Christopher ^a   Van Den Berg, John ^b  

^a Lewin Group   (Netherlands)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; FRANCE; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; REIMBURSEMENT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; FLUVOXAMINE; FRANCE; HUMANS; MARKOV CHAINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031661851     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814040-00009     Document Type: Article

References (62)

1. Conti DJ, Burton WN. The economic impact of depression in a workplace. J Occup Med 1994; 36: 983-8
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorder in the United States. Arch Gen Psychiatry 1994; 51: 8-19
3. Burvill PW. Recent progress in the epidemiology of major depression. Epidemiol Rev 1995; 17: 21-31
4. Mintz J, Mintz LI, Arrud MJ, et al. Treatment of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761-8
5. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994; 5 (3): 249-64
6. Consensus Development Panel, National Institutes of Mental Health/National Institutes of Health. Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 1985; 142: 469-76
7. Kamlet MS, Paul N, Greenhouse J, et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995; 16: 17-40
8. Wells KB, Stewart A, Hays RD, et al. The functioning and well being of depressed patients: results from the medical outcomes study. JAMA 1989; 262: 914-9
9. Tollefson GD, Souêtre E, Thomander L, et al. Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes. Int Clin Psychopharmacol 1993; 8: 281-93
10. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524-8
11. Greenberg P, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405-18
12. Stoudemire A, Frank R, Hedemark N, et al. the economic burden of depression. Gen Hosp Psychiatry 1993; 54: 405-18
13. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191-5
14. Lecomte T. Aspects socio-économiques de la depression. Ann Med Interne 1989; 140: 687-90
15. Baldessarini RJ. Current status of antidepressants: clinical pharmacology and therapy. J Clin Psychiatry 1989; 50: 117-26
16. Finley PR. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28: 1359-69
17. Guze BH. Selective serotonin reuptake inhibitors: assessment for formulary inclusion. Pharmacoeconomics 1996; 9 (5): 430-42
18. Thase ME. Relapse and recurrence in unipolar major depression short-term and long term approaches. J Clin Psychiatry 1990; 51 (6 Suppl.): 51-7
19. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovers from an episode of major depression: a prospective study. Am J Psychiatry 1992; 149: 795-800
20. Montgomery SA. Long-term treatment of depression. Br J Psychiatry 1994; 165 Suppl. 26: 31-6
21. Montgomery SA. Antidepressants in long-term treatment. Annu Rev Med 1994; 45: 447-57
22. Agency for Health Care Policy and Research (AHCPR). Depression in primary care. Vol II: treatment of major depression. Washington, DC: AHCPR, 1993
23. WHO Mental Health Collaborating Centres. Pharmacotherapy of depressive disorders: a consensus statement. J Affect Disord 1989; 17: 197-8
24. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994; 97 Suppl. 6A: 24S-32S
25. Lejoyeux M, Léon E, Rouillon F. Prévalence et facteurs de risque du suicide et des tentatives de suicide. L'Encéphale 1994; 20: 465-503
26. Kapur S, Mieczkwoski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempts and suicide. JAMA 1992; 268: 3441-5
27. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry 1990; 51 (6 Suppl.): 60-9
28. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose and half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27: 139-45
29. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out patients. Br J Psychiatry 1991; 159: 394-8
30. Anderson IM, Tomenson BM. Treatment discontinuation with serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433-8
31. Stokes PE. Fluoxetine: a five year review. Clin Ther 1993; 15: 216-43
32. Wilde M, Whittington R. Paroxetine: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 1995; 8 (1): 62-81
33. Beasley CM, Sayler ME, Cunningham GE. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990; 20: 15: 193-200
34. Simon GE, Von Korff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993; 15: 399-408
35. Sclar DA, Robinson LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organisation. Clin Ther 1994; 16: 715-30
36. Bentkover JD, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics 1995; 8 (3): 223-32
37. Ashford JJ. fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as 'new' drugs with established fluvoxamine? Int Clin Psychopharmacol 1995; 9 Suppl. 4: 27-31
38. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
39. Nuijten MJC, Hardens M, Souêtre E. A Markov process analysis comparing the cost-effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8 (2): 159-68
40. Lapierre Y, Bentkover J, Schainbaum S, et al. Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370-7
41. Barr J, Schumacher GE. Using decision analysis to conduct parmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott Raven, 1996: 1197-214
42. Beck JR, Pauker SG. The markov process in medical prognosis. Med Decis Making 1983; 3: 419-58
43. Sonnenberg F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
44. Clinical practice guideline: depression in primary care, treatment of major depression (AHCPR Publication No. 93-0551). Public Health Service, Agency for Health Care Policy and Research, Rockville, Maryland: 1993
45. Data on file, Solvay Duphar B.V, 1996
46. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis in recurrent depression. Int Clin Psychopharmacol 1993; 8: 189-95
47. Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in the prevention of relapses following acute treatment depression. Acta Psychiatr Scand 1995; 91: 189-94
48. Loo H, Dufour GH, Guelfi JD, et al. Long-term use of tianeptine in 38 depressed patients. Br J Psychiatry 1992; 160 Suppl. 15: 61-5
49. Stein MK, Rickels K, Weise C. Maintenance therapy with amitriptyline : a controlled trial. Am J Psychiatry 1990; 137: 370-1
50. Mindham R, Howland C, Shepard M. An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 1973; 3: 5-17
51. Glen A, Johnson A, Shepard M. Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized double blind controlled trial. Psychol Med 1984; 14: 37-50
52. Souètre E, Beuzen JN. Methodologie des etudes cout-benefice dans le developpment dun antidepresseur-exemple:prozac. Act Med Int Psychiatrie 1991; 8: 15-21
53. Broadhead WE, Blazer DG, George LK, et al. Depression, disability days and days lost from work in a prospective epidemiological survey. JAMA 1990; 264: 2524-8
54. Bilan du Monde L'analyse Economique et Societe 1995, Le Monde 1996
55. Organization for Economic Co-operation and Development (OECD). Main economic indicators. Paris: OECD, 1995
56. Editions du Vidal, Vidal, 1996
57. Caisses nationale d'Assurance Maladie des Travailleurs Salaries (CNAMTS). Carnets statistique 1995. No. 84. Paris: Le Regime General, 1994
58. Miller D, Sharon M. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52-8
59. Bolton S. Pharmaceutical statistics: practical and clinical applications. New York: Marcel Dekker, 1984
60. Task force on principles for economic analysis of health care technology. Economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 122: 61-70
61. Commonwealth Department of Health, Housing and Human Services. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee, Canberra' Australian Government Publishing Service, 1992
62. Torrance, GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9: 535-59